CGC-729 is under clinical development by Cure Genetics and currently in Phase I for Metastatic Renal Cell Carcinoma. According to GlobalData, Phase I drugs for Metastatic Renal Cell Carcinoma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CGC-729’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CGC-729 overview

CGC-729 is under development for the treatment of solid tumor and relapsed or metastatic advanced renal cell carcinoma. The therapeutic candidate comprises of NKT cells that are genetically engineered through CRISPR-Cas gene editing technology. It is administered through parenteral route and developed based on AIMS CAR-NKT platform.

Cure Genetics overview

Cure Genetics is a clinical stage biotechnology company that focuses on development of gene and cell therapies with research platforms for development of cancer and genetic diseases therapies and to meet unmet needs. It is headquartered in Suzhou, Jiangsu, China.

For a complete picture of CGC-729’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.